Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2001 1
2004 2
2005 1
2006 2
2007 1
2011 1
2013 1
2014 2
2015 3
2016 1
2017 3
2018 4
2019 3
2020 1
2021 1
2022 1
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK, Galle PR, Rimassa L, Heurgué A, Tam VC, Van Dao T, Thungappa SC, Breder V, Ostapenko Y, Reig M, Makowsky M, Paskow MJ, Gupta C, Kurland JF, Negro A, Abou-Alfa GK; HIMALAYA investigators. Sangro B, et al. Ann Oncol. 2024 May;35(5):448-457. doi: 10.1016/j.annonc.2024.02.005. Epub 2024 Feb 19. Ann Oncol. 2024. PMID: 38382875 Free article. Clinical Trial.
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski MA; SQUIRE Investigators. Thatcher N, et al. Lancet Oncol. 2015 Jul;16(7):763-74. doi: 10.1016/S1470-2045(15)00021-2. Epub 2015 Jun 1. Lancet Oncol. 2015. PMID: 26045340 Free article. Clinical Trial.
Point-of-Care Testing: General Aspects.
Ferreira CES, Guerra JCC, Slhessarenko N, Scartezini M, Franca CN, Colombini MP, Berlitz F, Machado AMO, Campana GA, Faulhaber ACL, Galoro CA, Dias CM, Shcolnik W, Martino MDV, Cesar KR, Sumita NM, Mendes ME, Faulhaber MHW, Pinho JRR, Barbosa IV, Batista MC, Khawali C, Pariz VM, Andriolo A. Ferreira CES, et al. Among authors: faulhaber acl. Clin Lab. 2018 Jan 1;64(1):1-9. doi: 10.7754/Clin.Lab.2017.170730. Clin Lab. 2018. PMID: 29479878 Review.
Clinical Applications of Point-of-Care Testing in Different Conditions.
Sumita NM, Ferreira CES, Martino MDV, Franca CN, Faulhaber ACL, Scartezini M, Pinho JRR, Dias CM, Cesar KR, Pariz VM, Guerra JCC, Barbosa IV, Faulhaber MHW, Batista MC, Andriolo A, Mendes ME, Machado AMO, Colombini MP, Slhessarenko N, Shcolnik W, Khawali C, Campana GA, Berlitz F, Galoro CA. Sumita NM, et al. Among authors: faulhaber acl. Clin Lab. 2018 Jul 1;64(7):1105-1112. doi: 10.7754/Clin.Lab.2018.171021. Clin Lab. 2018. PMID: 30146832 Review.
Event based coherence scanning interferometry.
Schober C, Pruss C, Faulhaber A, Herkommer A. Schober C, et al. Among authors: faulhaber a. Opt Lett. 2021 Sep 1;46(17):4332-4335. doi: 10.1364/OL.437489. Opt Lett. 2021. PMID: 34470020
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
Saad F, Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL, Jones R, McDermott R, Wirth M, Suzuki K, MacLean DB, Wang L, Akaza H, Nelson J, Scher HI, Dreicer R, Webb IJ, de Wit R; ELM-PC 4 investigators. Saad F, et al. Lancet Oncol. 2015 Mar;16(3):338-48. doi: 10.1016/S1470-2045(15)70027-6. Epub 2015 Feb 18. Lancet Oncol. 2015. PMID: 25701170 Clinical Trial.
Determination of rivaroxaban in patient's plasma samples by anti-Xa chromogenic test associated to High Performance Liquid Chromatography tandem Mass Spectrometry (HPLC-MS/MS).
Derogis PB, Sanches LR, de Aranda VF, Colombini MP, Mangueira CL, Katz M, Faulhaber AC, Mendes CE, Ferreira CE, França CN, Guerra JC. Derogis PB, et al. Among authors: faulhaber ac. PLoS One. 2017 Feb 7;12(2):e0171272. doi: 10.1371/journal.pone.0171272. eCollection 2017. PLoS One. 2017. PMID: 28170419 Free PMC article.
26 results